{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cold+Urticaria",
    "query": {
      "condition": "Cold Urticaria"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cold+Urticaria&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:04:33.162Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07266402",
      "title": "A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inducible Urticaria",
        "Cold Urticaria",
        "Cold-Induced Urticaria",
        "Symptomatic Dermographism"
      ],
      "interventions": [
        {
          "name": "Barzolvolimab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2026-01-15",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07266402"
    },
    {
      "nct_id": "NCT00685373",
      "title": "Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cryopyrin-Associated Periodic Syndromes",
        "Familial Cold Autoinflammatory Syndrome",
        "Muckle Wells Syndrome",
        "Neonatal Onset Multisystem Inflammatory Disease"
      ],
      "interventions": [
        {
          "name": "Canakinumab (ACZ885)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2008-05",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-04",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685373"
    },
    {
      "nct_id": "NCT00465985",
      "title": "Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muckle Wells Syndrome"
      ],
      "interventions": [
        {
          "name": "ACZ885",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 35,
      "start_date": "2007-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Madison, Wisconsin",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465985"
    },
    {
      "nct_id": "NCT03566615",
      "title": "Does the Cap Increase the Finding of Polyps When Water Exchange Colonoscopy is Used",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colonoscopy",
        "Polyp of Colon"
      ],
      "interventions": [
        {
          "name": "CAP-straight",
          "type": "DEVICE"
        },
        {
          "name": "CAP-daisy",
          "type": "DEVICE"
        },
        {
          "name": "water",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "VA Greater Los Angeles Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 1630,
      "start_date": "2018-07-01",
      "completion_date": "2023-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 2,
      "location_summary": "Mather, California • Palo Alto, California",
      "locations": [
        {
          "city": "Mather",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566615"
    },
    {
      "nct_id": "NCT05024058",
      "title": "Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inducible Urticaria"
      ],
      "interventions": [
        {
          "name": "Ligelizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2021-11-16",
      "completion_date": "2022-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-06-18",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 4,
      "location_summary": "Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        },
        {
          "city": "Murray",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024058"
    },
    {
      "nct_id": "NCT01211977",
      "title": "A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Muckle Wells Syndrome",
        "Autoinflammatory",
        "Behcet's Disease"
      ],
      "interventions": [
        {
          "name": "XOMA 052",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-08-27",
      "completion_date": "2011-04-29",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01211977"
    },
    {
      "nct_id": "NCT05812781",
      "title": "A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cryopyrin Associated Periodic Syndrome"
      ],
      "interventions": [
        {
          "name": "VTX2735",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zomagen Biosciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2023-03-18",
      "completion_date": "2024-03-06",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Columbus, Georgia",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812781"
    },
    {
      "nct_id": "NCT00288704",
      "title": "Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Cold Autoinflammatory Syndrome (FCAS)",
        "Familial Cold Urticaria",
        "Muckle-Wells Syndrome (MWS)",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "rilonacept 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2005-12",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-12-06",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288704"
    },
    {
      "nct_id": "NCT06931405",
      "title": "Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Inducible Urticaria",
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "BLU-808",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Blueprint Medicines Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2025-05-28",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06931405"
    },
    {
      "nct_id": "NCT00094900",
      "title": "Interleukin-1 Trap to Treat Autoinflammatory Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation",
        "Familial Mediterranean Fever",
        "Still's Disease, Adult-Onset"
      ],
      "interventions": [
        {
          "name": "IL-1 Trap",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2004-10",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-05-22T00:04:33.162Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094900"
    }
  ]
}